Results from phase 1 of the MANIFEST clinical trial to evaluate the safety and tolerability of pelabresib in patients with myeloid malignancies.

MLA

Stein, Eytan M., et al. “Results from Phase 1 of the MANIFEST Clinical Trial to Evaluate the Safety and Tolerability of Pelabresib in Patients with Myeloid Malignancies.” Leukemia & Lymphoma, vol. 65, no. 4, Apr. 2024, pp. 503–10. EBSCOhost, https://doi.org/10.1080/10428194.2023.2300710.

APA

Stein, E. M., Fathi, A. T., Harb, W. A., Colak, G., Fusco, A., & Mangan, J. K. (2024). Results from phase 1 of the MANIFEST clinical trial to evaluate the safety and tolerability of pelabresib in patients with myeloid malignancies. Leukemia & Lymphoma, 65(4), 503–510. https://doi.org/10.1080/10428194.2023.2300710

Chicago

Stein, Eytan M., Amir T. Fathi, Wael A. Harb, Gozde Colak, Andrea Fusco, and James K. Mangan. 2024. “Results from Phase 1 of the MANIFEST Clinical Trial to Evaluate the Safety and Tolerability of Pelabresib in Patients with Myeloid Malignancies.” Leukemia & Lymphoma 65 (4): 503–10. doi:10.1080/10428194.2023.2300710.